Two Sigma Advisers
VTGN icon

Two Sigma Advisers’s VistaGen Therapeutics VTGN Stock Holding History

Two Sigma Advisers’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-137,732
Closed -$91.2K – 2123
2025
Q4 		$91.2K Sell
137,732
-19,300
-12% -$69.7K ﹤0.01% 2237
2025
Q3 		$557K Buy
157,032
+131,200
+508% +$392K ﹤0.01% 1719
2025
Q2 		$51.7K Buy
25,832
+15,100
+141% +$34.3K ﹤0.01% 2251
2025
Q1 		$26.8K Sell
10,732
-1,300
-11% -$3.68K ﹤0.01% 2346
2024
Q4 		$35.5K Buy
+12,032
New +$33.9K ﹤0.01% 2307
2023
Q1 		– Sell
-1,117
Closed -$3.45K – 2764
2022
Q4 		$3.45K Sell
1,117
-6,696
-86% -$25.2K ﹤0.01% 2483
2022
Q3 		$36K Buy
+7,813
New +$77.4K ﹤0.01% 2398
2022
Q2 		– Sell
-13,667
Closed -$508K – 2887
2022
Q1 		$508K Sell
13,667
-19,626
-59% -$856K ﹤0.01% 1978
2021
Q4 		$1.95M Sell
33,293
-3,690
-10% -$240K ﹤0.01% 1215
2021
Q3 		$3.04M Buy
36,983
+15,950
+76% +$1.39M 0.01% 1029
2021
Q2 		$1.99M Sell
21,033
-2,490
-11% -$184K 0.01% 1303
2021
Q1 		$1.5M Buy
23,523
+19,580
+497% +$1.31M ﹤0.01% 1416
2020
Q4 		$230K Buy
3,943
+2,983
+311% +$76.1K ﹤0.01% 2119
2020
Q3 		$20K Buy
+960
New +$19.9K ﹤0.01% 2361

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers's VTGN Position: Q1 2026 in Review

Two Sigma Advisers sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 137,732 shares — an estimated $91.2K sold.

Two Sigma Advisers first reported a position in VTGN in Q3 2020 and held it in 14 quarters. The position peaked at $3.04M in Q3 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Two Sigma Advisers reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 137,732 VistaGen Therapeutics shares in Q1 2026, an estimated $91.2K.
  • Two Sigma Advisers first reported a position in VistaGen Therapeutics in Q3 2020 and held it in 14 quarters.
  • Two Sigma Advisers's VistaGen Therapeutics position peaked at $3.04M in Q3 2021.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.